The Company's independent directors raised
opinions to board resolutions.
Date of events
2022/03/22
To which item it meets
paragraph 44
Statement
1.Meeting date of the board of directors, audit committee or remuneration
committee:2022/03/22
2.Contents of the resolution made by the board of directors, audit committee
or remuneration committee (please enter "board of directors","audit
committee"or "remuneration committee"):board of directors
3.Name and resume of independent director(s) or member(s) of the
audit/remuneration committee that expressed an objection or reserved opinion:
1.Independent directors/Tsai,Gan-Ren.
2.Independent directors/Kuo, Li-Jen.
3.Independent directors/Lu,Hsueh-Yu.
4.Motion(s) against which the objection or qualified opinion was expressed:
The seventh resolution, the proposal of re-election of the Board of
Directors in 2022 General Shareholders' Meeting.
5.Objection or reserved opinion by the aforementioned independent
director(s) or member(s) of the audit/remuneration committee:
The proposal is to elect seven directors (including three independent
directors)for the tenth term. Director TS Chiang proposed an amendment:
the number@of directors should be revised to nine (including three
independent directors).
Opinions of the independent directors are as follows:
1.Independent directors/Tsai,Gan-Ren.: At present, there are 7 directors,
and the number of directors will be increased to 9 in the future. You can
listen to more opinions.
It is not a bad thing to think broadly.I agree with Director TS Chiang's
proposal.
2.Independent directors/Kuo, Li-Jen: The number of directors can be added
in consideration of future needs and regulatory requirements in advance .
I agree with Director TS Chiang's proposal.
3.Independent directors/Lu,Hsueh-Yu: In response to the abolition of
supervisors and the establishment of an audit committee, as well as changes
in the environment and other related conditions, the company should adapt
to the number of directors.I agree with Director TS Chiang's proposal.
The three independent directors agreed with the amendment proposed by
Director TS Chiang.
6.Countermeasures:
Disclose material information to the public in accordance with regulations.
7.Any other matters that need to be specified:
The resolution was put to a voting.Elect 9 Directors (including three
Independent Directors). Four Board members supported TS Chiang amendment,
whilst Three Board members supported the original resolution to elect
7 Directors (including three Independent Directors) of the 10th Board
of Directors. The resolution was passed the amendment.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bionime Corporation published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 12:01:04 UTC.
Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.
BIONIME CORPORATION 
